Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study

NCT00145444 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Psychotic Disorders

Interventions

DRUG: olanzapine
DRUG: ziprasidone

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.